67 related articles for article (PubMed ID: 12833655)
1. Interleukin-1 as a therapeutic target in TTP.
Ali SA; Gardiner EE
Blood; 2024 Jun; 143(26):2686-2688. PubMed ID: 38935360
[No Abstract] [Full Text] [Related]
2. Axokine (Regeneron).
Preti A
IDrugs; 2003 Jul; 6(7):696-701. PubMed ID: 12861475
[TBL] [Abstract][Full Text] [Related]
3. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.
Baum A; Fulton BO; Wloga E; Copin R; Pascal KE; Russo V; Giordano S; Lanza K; Negron N; Ni M; Wei Y; Atwal GS; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
Science; 2020 Aug; 369(6506):1014-1018. PubMed ID: 32540904
[TBL] [Abstract][Full Text] [Related]
4. Structure, heterogeneity and developability assessment of therapeutic antibodies.
Xu Y; Wang D; Mason B; Rossomando T; Li N; Liu D; Cheung JK; Xu W; Raghava S; Katiyar A; Nowak C; Xiang T; Dong DD; Sun J; Beck A; Liu H
MAbs; 2019; 11(2):239-264. PubMed ID: 30543482
[TBL] [Abstract][Full Text] [Related]
5. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.
Haugh IM; Preston AK; Kivelevitch DN; Menter AM
Drug Des Devel Ther; 2018; 12():3879-3883. PubMed ID: 30518998
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.
Shah DK
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):553-71. PubMed ID: 26373957
[TBL] [Abstract][Full Text] [Related]
7. Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review.
Jotanovic Z; Mihelic R; Sestan B; Dembic Z
Drugs Aging; 2012 May; 29(5):343-58. PubMed ID: 22550965
[TBL] [Abstract][Full Text] [Related]
8. [Cryopyrin-associated periodic syndrome].
Kümmerle-Deschner JB
Z Rheumatol; 2012 Apr; 71(3):199-208. PubMed ID: 22527214
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis.
Cardiel MH; Tak PP; Bensen W; Burch FX; Forejtova S; Badurski JE; Kakkar T; Bevirt T; Ni L; McCroskery E; Jahreis A; Zack DJ
Arthritis Res Ther; 2010; 12(5):R192. PubMed ID: 20950476
[TBL] [Abstract][Full Text] [Related]
10. Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.
Pelletier JP; Martel-Pelletier J; Raynauld JP
Arthritis Res Ther; 2006; 8(2):206. PubMed ID: 16569256
[TBL] [Abstract][Full Text] [Related]
11. [Elaboration of objective methods of clinical evaluation of new antirheumatic drugs].
Sigidin IaA; Tsvetkova ES
Vopr Revm; 1976; (3):18-23. PubMed ID: 793175
[No Abstract] [Full Text] [Related]
12. Cilengitide Merck.
Smith JW
Curr Opin Investig Drugs; 2003 Jun; 4(6):741-5. PubMed ID: 12901235
[TBL] [Abstract][Full Text] [Related]
13. Monotonicity of interleukin-1 receptor-ligand binding with respect to antagonist in the presence of decoy receptor.
Gnacadja G; Shoshitaishvili A; Gresser MJ; Varnum B; Balaban D; Durst M; Vezina C; Li Y
J Theor Biol; 2007 Feb; 244(3):478-88. PubMed ID: 17011587
[TBL] [Abstract][Full Text] [Related]
14. IL-1 trap. Regeneron/Novartis.
Gabay C
Curr Opin Investig Drugs; 2003 May; 4(5):593-7. PubMed ID: 12833655
[TBL] [Abstract][Full Text] [Related]
15. ["There are still differences between non-steroidal anti-rheumatic drugs". G. L. Bach, Bayreuth, elaborates on the clinical significance of interleukin 1 inhibition].
Bach GL
Fortschr Med; 1989 Mar; 107(7):71-2. PubMed ID: 2785077
[No Abstract] [Full Text] [Related]
16. CDP-870. Celltech/Pfizer.
Rose-John S; Schooltink H
Curr Opin Investig Drugs; 2003 May; 4(5):588-92. PubMed ID: 12833654
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
